PMID- 36097299
OWN - NLM
STAT- MEDLINE
DCOM- 20221110
LR  - 20221110
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 29
IP  - 13
DP  - 2022 Dec
TI  - S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA 
      (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial.
PG  - 8198-8206
LID - 10.1245/s10434-022-12490-4 [doi]
AB  - BACKGROUND: To date, no clinical trials on the use of induction therapy before 
      surgery have focused solely on lung squamous cell carcinoma (LSCC). We report the 
      results of the Personalized Induction Therapy-2 (PIT-2) trial, a multicenter 
      phase II study, performed to investigate the efficacy and safety of S-1 + 
      cisplatin with concurrent thoracic radiotherapy (TRT) followed by surgery in 
      patients with stage IIIA (N2) LSCC. METHODS: Patients with pathologically proven 
      stage IIIA (N2) LSCC received induction therapy comprising three cycles of S-1 + 
      cisplatin with concurrent TRT (45 Gy in 25 fractions) followed by surgery. S-1 
      was administered orally at a dose of 40 mg/m(2) twice daily on days 1-14, in 
      addition to intravenous infusion of cisplatin (60 mg/m(2)) on day 1. The primary 
      endpoint was 2-year progression-free survival (PFS) rate. RESULTS: Of 45 
      registered patients, 43 underwent induction therapy. Of the 43 patients, 39 (91%) 
      underwent surgery (35 lobectomies, 3 pneumonectomies, and 1 wedge resection). The 
      2-year PFS, 2-year overall survival, objective response rate, and pathological 
      complete response rates were 67% (90% confidence interval [CI] 54-78%), 70% (95% 
      CI 53-81%), 86% (95% CI 76-96%), and 39% (95% CI 23-54%), respectively. No new 
      treatment-related adverse events occurred during the induction therapy. One case 
      of 90-day postoperative mortality involving a patient who underwent right 
      pneumonectomy and developed pneumonia after discharge occurred. CONCLUSIONS: 
      Induction therapy using S-1 + cisplatin with concurrent TRT followed by surgery 
      is a feasible and promising treatment approach for stage IIIA (N2) LSCC.
CI  - (c) 2022. Society of Surgical Oncology.
FAU - Takamochi, Kazuya
AU  - Takamochi K
AD  - Department of General Thoracic Surgery, Juntendo University School of Medicine, 
      Tokyo, Japan. ktakamo@juntendo.ac.jp.
FAU - Tsuboi, Masahiro
AU  - Tsuboi M
AD  - Department of Thoracic Surgery and Oncology, National Cancer Center Hospital 
      East, Kashiwa, Japan.
FAU - Okada, Morihito
AU  - Okada M
AD  - Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
FAU - Niho, Seiji
AU  - Niho S
AD  - Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 
      Japan.
FAU - Ishikura, Satoshi
AU  - Ishikura S
AD  - Department of Radiology, Nagoya City University Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Oyamada, Shunsuke
AU  - Oyamada S
AD  - Department of Biostatistics, JORTC Data Center, Tokyo, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Suzuki, Kenji
AU  - Suzuki K
AD  - Department of General Thoracic Surgery, Juntendo University School of Medicine, 
      Tokyo, Japan.
CN  - Advanced Clinical Trial Chest Surgery Group (ACTG)
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220912
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Cisplatin
MH  - *Lung Neoplasms
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Combined Modality Therapy
MH  - Treatment Outcome
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - *Testicular Neoplasms/drug therapy
MH  - Lung/pathology
MH  - Neoplasm Staging
FIR - Tanaka, Fumihiro
IR  - Tanaka F
FIR - Tsuchida, Masanori
IR  - Tsuchida M
FIR - Yoshino, Ichiro
IR  - Yoshino I
FIR - Shiono, Satoshi
IR  - Shiono S
FIR - Oizumi, Hiroyuki
IR  - Oizumi H
FIR - Haruki, Tomohiro
IR  - Haruki T
FIR - Okumura, Norihito
IR  - Okumura N
FIR - Kazuhito, Funai
IR  - Kazuhito F
FIR - Ito, Hiroyuki
IR  - Ito H
FIR - Horio, Hirotoshi
IR  - Horio H
FIR - Matsuura, Motoki
IR  - Matsuura M
FIR - Ueno, Tsuyoshi
IR  - Ueno T
FIR - Tagawa, Tetsuzo
IR  - Tagawa T
EDAT- 2022/09/14 06:00
MHDA- 2022/11/11 06:00
CRDT- 2022/09/13 00:13
PHST- 2022/06/29 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2022/11/11 06:00 [medline]
PHST- 2022/09/13 00:13 [entrez]
AID - 10.1245/s10434-022-12490-4 [pii]
AID - 10.1245/s10434-022-12490-4 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2022 Dec;29(13):8198-8206. doi: 10.1245/s10434-022-12490-4. Epub 
      2022 Sep 12.